Clinical Trials Related to NRG Oncology

Related studies linked through entity extraction aliases.

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Status: RECRUITING
Phase: PHASE3

Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

Status: RECRUITING
Phase: PHASE2

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Status: RECRUITING
Phase: PHASE3

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Status: RECRUITING
Phase: PHASE2

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1/PHASE2

SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer

Status: RECRUITING
Phase: PHASE3

Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Status: RECRUITING
Phase: PHASE2

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

Status: RECRUITING
Phase: PHASE2

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Status: RECRUITING
Phase: PHASE3

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Status: RECRUITING
Phase: PHASE2/PHASE3

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Status: RECRUITING
Phase: PHASE2

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

Status: RECRUITING
Phase: NA

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Status: SUSPENDED
Phase: PHASE2/PHASE3

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer

Status: TERMINATED
Phase: NA

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Status: RECRUITING
Phase: PHASE3